Background: An estimated 1.2 million American adults engage in sexual and drug use behaviors that place them at significant risk of acquiring HIV infection. Engagement in health care for the provision of daily oral antiretroviral medication as preexposure prophylaxis (PrEP), when clinically indicated, could substantially reduce the number of new HIV infections in these persons. However, resources to cover the financial cost of PrEP care are anticipated barriers for many of the populations with high numbers of new HIV infections.
INTRODUCTION
The Centers for Disease Control and Prevention (CDC) estimates that 1.2 million persons in the United States have sexual or injection behaviors that place them at substantial risk of acquiring HIV infection. 1 These adults would benefit from the use of daily oral antiretroviral preexposure prophylaxis (PrEP), which has been proven both safe and highly effective in reducing HIV infections for gay, bisexual and other men who have sex with men (MSM), heterosexually active females and males (HET), and persons who inject drugs not prescribed to them (PWID). The Food and Drug Administration approved PrEP as an indication for daily coformulated tenofovir disoproxil fumarate and emtricitabine (brand name Truvada) in 2012, and CDC issued clinical practice guidelines for PrEP in 2014. 2 The affordability of medication, laboratory testing, and clinical care visits required for the safe prescription and monitoring of PrEP is a critical issue for its access by those who would benefit from its use. PrEP is being implemented in the United States at the same time as changes in the health care insurance landscape resulting from the Patient Protection and Affordable Care Act (ACA) enacted in 2010. Several studies have found that the anticipation of high cost is a barrier to the acceptability of PrEP use as an HIV prevention method. 3, 4 However, in 1 study of 30 financially disadvantaged users PrEP users in Mississippi, 5 all had successfully accessed PrEP despite initial perceived concerns about costs. "While many participants noted that they had initially perceived the high cost of PrEP as a potential barrier to use, those barriers were overcome with the industry sponsored medication assistance program, which pays for PrEP for uninsured patients and provides assistance with medication copayments for insured individuals." Loss of employment resulting in loss of insurance, and lack of knowledge of the medication assistance program led one participant to stop using PrEP. Although anticipated concerns about coverage of PrEP costs have been widely discussed online, 6 no published studies to document the scale of the problem were available, so we assessed the extent to which insurance and PrEP assistance plans will meet the anticipated need.
METHODS

Population Inputs
Data from national population-based surveys were analyzed to estimate the percentages and numbers of persons with indications for PrEP as previously described. 1 Using the same population-based surveys, we estimated the percentages and number of persons with PrEP indications by insurance type and federal poverty level (FPL) for each of the 3 major HIV transmission risk populations, MSM, HET, and PWID. Insurance type was categorized hierarchically into private insurance, public insurance, and no health insurance coverage. For MSM and HET, public insurance included Medicare, Medicaid, Medi-Gap, Indian Health Service, SCHIP, military health care (Champus, Champ/VA), state-sponsored health plan, and other government insurance, and no health insurance was defined as the absence of private or public insurance or insured by only a single payer. 7, 8 For PWID, public insurance included Medicare, Medicaid, Medi-Gap, SCHIP, military health care (Champus, Champ/VA), or other insurance, and no health insurance was the absence of private or public insurance. 9 FPL was categorized into the estimated percentage and the number of persons with household FPL of ,500% or greater than or equal to 500%. The National Health and Examination Survey and National Survey of Family Growth already produce a calculated variable, Adaptations are themselves works protected by copyright. So in order to publish this adaptation, authorization must be obtained both from the owner of the copyright in the original work and from the owner of copyright in the translation or adaptation.
* 10 Finally, the percentage of uninsured persons ineligible for coverage because of immigration status, and uninsured persons in the coverage gap, were based on the Kaiser Family Foundation report, "The Uninsured: A Primary." 11 
Cost Inputs
The costs of PrEP medication, clinical visits, and laboratory costs were identified from various sources. The Red Book was used to identify the 2016 average wholesale price for a 30-day supply of Truvada. 12 The estimated 340B pricing is equal to 51% of the average wholesale price. 13 The costs of clinical visits for the first year on PrEP were based on estimates reported by the American Medical Association for specified visit common procedural terminology billing codes. 14 Finally, laboratory costs for tests recommended for the first year a person is taking PrEP were based on the Health Care Blue Book 15 and personal communication on Federally Qualified Health Center (FQHC) cost for fourth-generation HIV test through a major commercial laboratory (Table 1) .
Estimating Persons With PrEP Indications in Need of Assistance for All PrEP Medication and Care or PrEP Care Only Figure 1 illustrates the logic of the analysis used to identify persons in need of financial assistance for PrEP care. For each transmission risk group, the health insurance status was identified as described above. For persons who had private or public insurance, based on reports from recent observational studies, we assumed that 1% of persons may have coverage for PrEP denied by their insurance and were therefore in need of assistance ( Fig. 1, 2a ). For persons who were uninsured, we then estimated that 15% of persons were undocumented ( Fig. 1, 2b ) and 10% of persons were living in a state that did not expand Medicaid coverage (Fig. 1, 2c ). 11 These persons were not eligible for traditional Medicaid or ACA marketplace subsidies (in the coverage gap) and therefore in need of assistance. For persons who had private or public insurance coverage, we estimated the percentage and number who had insurance coverage that did cover PrEP care; these persons were not considered in need of assistance ( Fig. 1, 3a) . For persons who were uninsured, we estimated the percentage and number who were documented and not in the coverage gap; these persons were not considered in need of assistance ( Fig. 1, 3b ).
Of those identified as in need of assistance, some persons could obtain medication at no cost through the Medication Assistance Program (MAP) offered by Gilead Sciences to uninsured US residents whose household FPL was ,500%. By insurance coverage, we estimated the percentage of persons who had a FPL of ,500% and identified those persons as in need of financial assistance for the cost of clinical visits and laboratory tests (PrEP care) if they obtained medication through Gilead's MAP (Fig. 1, 4a ). Those with a FPL greater than or equal to 500% were not eligible for Gilead's MAP and therefore in need of financial assistance for the costs of medication, clinical visits, and laboratory tests (ie, all PrEP medication and care) (Fig. 1, 4b) .
Costs for medication, clinical visits, and laboratory costs were calculated by transmission risk population when recommendations varied by group. Laboratory tests varied by transmission category and sex, and included 4 HIV antibody tests, 1 fourth-generation HIV test, 2 basic metabolic panels, 1 pregnancy test (females only), 1 hepatitis B serology test, 5 syphilis tests for MSM and 2 syphilis tests for the other transmission risk groups, and 15 nucleic acid amplification tests for gonorrhea and chlamydia (nucleic acid amplification test GC/CT) for MSM and 2 for the other transmission risk groups per year (Table 1B) .
Based on the estimated number of persons by transmission risk category in need of financial assistance for all PrEP medication and care or for PrEP care but not medication, we estimated the cost per transmission risk group and the estimated total number of persons and cost if a payer of last resort program were to pay for medication, clinical visits, or laboratory tests among persons with indications for PrEP use who were uninsured or whose insurers denied coverage for PrEP.
Sensitivity analyses estimating the effect of varying 2 key inputs were conducted. The first sensitivity analysis accounted for the variability in the estimated number of persons with indications for PrEP by transmission risk group. We estimated lower and upper bound inputs by calculating the midpoint between the point estimate (Table 1 ) and the 95% confidence intervals, that is, point estimate 2 [(point estimate 2 lower 95% confidence interval)/2]. 1 The second sensitivity analysis accounted for the variability in the estimated percentage of persons in households with FPL of ,500% by insurance coverage. Again, we estimated the lower and upper bound inputs by calculating the midpoint between the point estimate and the associated 95% confidence intervals (not reported).
RESULTS
Our analyses of population-based survey data for 2015 estimates that of adults with PrEP indications, 64% of MSM had private insurance, 11% had public insurance, and 25% were uninsured; 49% and 51% of heterosexual females and heterosexual males, respectively, had private insurance, 27% and 20% had public insurance, and 24% and 29% were uninsured; however, among PWID, 21% had private insurance, 29% had public insurance, and 50% were uninsured (Fig. 2) . The percentage of adults with PrEP indications living at a FPL ,500% varied by transmission risk category and insurance coverage (Table 1 ).
An estimated 50,800 persons with PrEP indications (Table 2) were undocumented US residents, comprising 15% of the uninsured. An estimated 36% of undocumented persons with PrEP indications were MSM, 34% were heterosexual females, 13% were heterosexual males, and 17% were PWID. An estimated 33,900 persons with PrEP indications were in the coverage gap, comprising 10% of the uninsured.
The estimated number of MSM, heterosexual females, heterosexual males, and PWID with indications for PrEP in need of any financial assistance is shown in Table 2 . Based on the analysis algorithm ( Fig. 1) , an estimated 34,200 MSM (7%) are in need of PrEP payment assistance, 30,500 of The estimated number of persons in need of financial assistance for both PrEP medications and associated health care (Table 3 ) was 2600 MSM, 3500 heterosexual females, 100 PWID females, 1000 heterosexual males, and 100 PWID males. In all transmission risk group populations, the number in need was ,1% of those with indications for PrEP use. At Medicaid reimbursement rates for clinical care and 340B pricing for medicines, the estimated annual cost of PrEP medications and care per person was $12,913 for MSM, $11,711 for heterosexual and PWID females, and $11,694 for heterosexual and PWID males.
The estimated number of persons in need of financial assistance for PrEP care alone (for clinical visits and laboratory tests but not PrEP medication) was 31,700 MSM, 28,500 heterosexual females, 7000 PWID females, 11,400 heterosexual males, and 7000 PWID males. At Medicaid reimbursement rates for clinical care (including laboratory tests), the estimated annual cost of PrEP care per person was $2143 for MSM, $941 for heterosexual and PWID females, and $924 for heterosexual and PWID males.
The average wholesale price of Truvada was $1759.73, 16 whereas the estimated 340B price available to many federally funded clinics was $897.46. 13 Clinical visit costs summed to $422.21 for the first year for all persons with PrEP indications. At FQHC prices (Table 3) , the cost of PrEP medication was 89% of costs in the first year of care, laboratory tests were 8%, and charges for clinical care visits were 3%.
Across all transmission risk group populations, an estimated 7300 persons are in need of assistance for both PrEP medication and care, with an estimated annual cost of $88.9 million. In addition, 83,300 persons are in need of assistance for PrEP care only, with an estimated annual cost of $119.0 million. Of the 1.2 million adults with PrEP indications, ,1% are in need of financial assistance for both PrEP medication and care and 7% are need of assistance for PrEP care only.
Sensitivity analyses found that using the calculated lower and upper bound inputs for the estimated number of persons with PrEP indications as described above, the number of persons in need of financial assistance ranged from 68,900 to 118,300 persons, resulting in a range of annual costs of $153.3 million to $262.5 million. Using the calculated lower and upper bound inputs for the estimated percentage of persons in households with FPL of ,500%, the number of persons in need of financial assistance remained the same (93,600) with estimated annual costs ranging from $177.6 million to $243.8 million.
DISCUSSION
To inform ongoing discussions about supporting financial access to PrEP medication and associated health care for persons at substantial risk of HIV acquisition, it is important to have a measure of the extent of coverage already available and the size of the population in need of additional resources. We obtained these estimates by applying nationally representative data on 1) public and private insurance coverage, and 2) for the uninsured, data on household income and criteria for ACA insurance or the pharmaceutical PrEP medication assistance plan, to a prior assessment of the number of persons with indications for PrEP use in the United States. 1 In summary, we found that few persons with indications for PrEP use have an entirely unmet need for financial coverage of medication and/or associated clinical care costs. Of persons estimated to have indications for its use, 75% of MSM, 76% of heterosexual females, 71% of heterosexual 18 An estimated 75% of those who are uninsured are eligible by income for ACA insurance through federal or state exchanges. Of those with no access to private, public, or ACA insurance, 92% are eligible by household income for PrEP medication at no cost through the Gilead MAP. 17 These persons will benefit from insurance navigation services to enroll in ACA or other health care insurance for which they are eligible or assistance to enroll in the Gilead MAP if not insurable. In addition, PrEP has been nominated for review by the US Preventive Services Task Force. If it receives an A or B rating as a recommended preventive service, some cost elements may be reduced for those with health insurance.
Less than 1% of persons with indications for PrEP are not insured, not eligible for ACA insurance, and ineligible for MAP, resulting in an entirely unmet need for financial assistance for all elements of PrEP care. Many of these persons can receive subsidized care through sliding fee schedules at FQHC and other safety-net clinics but will still have problems with drug costs that may be prohibitive. For them, a number of solutions are being considered or have been implemented, including state PrEP assistance plans (payer of last resort plans), some of which cover only the medication 19 and some of which cover only the clinical visit and laboratory costs. 20 In all cases, navigation and linkage to PrEP care services by community workers, social workers, nurses, or others will aid in having more people with indications for its use aware of PrEP and able to access the necessary clinical care to receive it. Equally important, financial benefits navigation for all PrEP patients to ensure that they retain all coverage benefits as their employment status, income, residence, or other life circumstances change will be critical to retention in PrEP care and protective levels of medication adherence. Loss of insurance coverage leading to medication nonadherence has been associated with the acquisition of HIV infection in cohorts of PrEP patients. 21 The national cost of covering PrEP for all persons with indications for its use in need of assistance is significant, an estimated $208 million annually, including both those who need help with clinical care costs only ($119 million) and those who need help with both medication and clinical care costs ($89 million). For comparison, the FY16 federal budget allocates 19.7 billion dollars for the treatment and health care for persons already living with HIV infection, approximately 75% of the domestic funding for HIV. 22 In addition, although there is evidence that PrEP uptake is increasing rapidly in some locations [23] [24] [25] particularly among MSM, there are only estimated to be approximately 80,000 persons who were prescribed PrEP in 2012-2015 nationwide 26 or approximately 6% of the number who we estimate would benefit from its use. At current rates of uptake, it will be some time before all persons in need of financial assistance are attempting to access PrEP services.
Another key concern is that PrEP is not currently accessed equitably in the geographic areas (eg, the southern United States) and subpopulations (eg, young African American MSM and women) experiencing the most severe disparities in rates of new HIV infections. 27 Given our analysis and the current financial burden in some subpopulations, existing inequities are likely to be exacerbated, especially among undocumented persons who are ineligible for most forms of federally funded health insurance.
There are several limitations of the analysis that merit consideration. Although we are unaware of any insurance, public or private, that has a formal policy not to cover PrEP care, we have used an estimate of 1% noncoverage to allow for the likelihood that we are unaware of the few plans that do not cover it, as well as the unknown proportion of coverage that is declined in error (ie, despite no formal policy of noncoverage). This may be overestimating the number of insured persons who need financial assistance. There is a complex array of deductibles, copay, and coinsurance rates that apply to the range of insurance options depending on the level of plan chosen. Within each level, some plans have deductible limits for medications separate from the limit for all other expenses; some have a deductible for each individual in a family separate from the deductible for the family as a whole. This analysis does not include these potential out-ofpocket costs explicitly, although we do use income to assess eligibility for copay/coinsurance assistance and experience to date suggests that residual costs are affordable for most.
There are at least 3 areas where public health systems can leverage opportunities to support provision of PrEP as a clinical HIV prevention service: (1) linking clinical and community prevention, (2) supporting the development of alternative payment methodologies to cover communitybased and clinical prevention services, and (3) using epidemiologic knowledge to ensure access to PrEP for populations at the highest risk of HIV acquisition. Public health has a key role in developing and reinforcing systems to provide clinical and community prevention services. 28 
CONCLUSIONS
PrEP is an important new tool for HIV prevention and its expanded use is supported by several federal agency efforts, including the National HIV/AIDS Strategy. The Food and Drug Administration-approved use of Truvada for PrEP has been widely available for 4 years, but many people who can benefit from PrEP are not yet being prescribed it. The causes for this are varied, but concern is frequently raised about the costs of the daily medication, and the ongoing periodic clinical visits and laboratory testing recommended by the Public Health Service clinical practice guidelines issued by CDC to ensure its safe and effective use. This study found that a small number of patients would not be financially covered for their clinician visits and laboratory tests, and an even smaller number would have no coverage for medication, as well as the clinical costs of PrEP care. If the eligibility for different types of insurance, medication, or copay assistance programs changes substantially in coming years, it will impact the financial feasibility of scaling up PrEP use to the many who would benefit from its use. This information on PrEP care costs, insurance coverage, and unmet financial need among persons in key HIV
